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Abstract 
Natural products are the best source for various medicinal drugs. Regardless investigate the toxic effect of these 
plant extracts, the results will still unsafe and unacceptable. This study aimed to identify anti-cancer activity and 
cytotoxicity effect of Momordica charantia extract on different cancer cell line. Materials and Methods:to 
archive the aim of this study 3 different cancer cell lines (HCT116, MCF-7, and HepG2) were treated with 
different Momordicacharantiaextract doses (from 0-100µg) for each cell line. IC50, cell viability,apoptosis, were 
evaluated. Results:The effect of Momordicacharantiaextract was highly significant in HepG2 cells than HCT116 
cell as well as MCF-7 which showing the IC50 of Momordicacharantia extract in HepG2 was 0.77 µg/ml while 
in HCT116 was 0.81µg/mland was 1.35µg/ml in MCF-7 cells respectively. Also, the effect of the 
Momordicacharantia extract was more potent in HCT116 compared to MCF-7 cells.Conclusions: in the light of 
these resultsMomordicacharantiaextract may use as anticancer pro-drugat a specific type of cancer (Liver 
HepG2 cell line) but still need further studies to explore the mechanism of action that led to observe different 
results from different cell lines despite the same extract. 
Keywords: Momordicacharantia, Apoptosis, MCF-7, HepG2, HCT116. 
1.Introduction 
Natural products possess valuable, essential molecules and chemical groups which form the pool for the 
different drugs. 
With the steady increase of the importance of natural products to use in different purposes, for 
pharmaceutical, food, antibiotics, insecticide, etc. the anti-cancer drug research and development field acquired 
new and strong momentum. So far, there are many anti-cancer drugs have been discovered. Despite, they have 
an anti-cancer effect on different cancer types, the mechanism of action of many drugs still unknown. 
One of the most simple, least expensive, reliable, short-time in-vitro anticancer activity screening tests 
is apoptotic, IC50, and cell viability. All of these tests can use together as different parameters useful to screen 
positive and negative effects of many plant extracts, potential anticancer drugs and so on (Wang et al., 2006) 
many societies (Indian and Turkish) used Momordica charantiain their own folk medicine for treating different 
antidiabetic, abortifacient, anthelmintic, contraceptive, dysmenorrhea, eczema, emmenagogue, antimalarial, 
galactagogue, gout, jaundice, abdominal pain, kidney (stone), laxative, leprosy, leucorrhea, piles, pneumonia, 
psoriasis, purgative, rheumatism, fever and scabies) (Zhao et al., 2015). (Licastro et al., 1980) have investigated 
the toxicity of Momordica charantia lectin as an inhibitor for human normal and leukemic lymphocytes, 
while(Pongnikorn et al., 2003), studied the effect of the plant (MC) on level and function of natural killer cells in 
cervical cancer patients with radiotherapy. With the continued interest, many researchers showed different effect 
of (MC) plant on different type of cancers in vivo and in vitro (Brennan et al., 2012; Fang et al., 2012a; Fang et 
al., 2012b; Weng et al., 2013; Yung et al., 2015).  
The splendor of the impact of this plant makes the researchers going to do more investigations on different 
cancer types.  
   Under the influence of previous research, cytotoxicity effect of (MC) plant on HepG2, MCF7 and HCT116 
cancer cells were evaluated by means of IC50. Consequently, our study has been designed to fill the avoid data 
regarding the effect of (MC) plant extract. 
 
2.Materials and Methods: 
2.1 Plant materials 
Momordica charantia freshaerial parts were purchased from locally market. 
2.2 Chemicals and drugs: 
SulphoRhodamine-B (SRB), ethanol and methanol were purchased from Sigma Chemical Co. (St. 
Louis, MO, USA). Culture media and growth supplements were purchased from Gibco / Life Technologies Co, 
(Carlsbad, CA, USA). Cell culture vessels were purchased from Nunc Co.  (Roskilde, Denmark). 
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2.3 Cell culture  
Human colorectal carcinoma (HCT 116), Human hepatic carcinoma (HEPG-2) and Human breast cancer (MCF-
7)  were obtained from Vacsera (Giza, Egypt). Cells were maintained in RPMI media supplemented with 100 
µg/mL streptomycin, 100 units/ml penicillin and 10% heat-inactivated fetal bovine serum in a humidified, 5% 
(v/v) CO2 atmosphere at 37 ºC, the cells were sub-cultured tow times in a week . 
2.4 Preparation of Plant extract  
The aqueous plant extract was prepared by washed in distilled water and air-dried overnight then the fleshy parts 
were cut into small pieces and fine powdered. The aqueous plant extract was left in the water bath (Fisher 
Scientific-2232, USA) for 1 hr. at 60 C̊ then leave overnight at room temperature. The extract was filtered with 
filter paper. The filtrates were combined and concentrated using vacuum rotatory evaporator system (HB-10, 
IKA) and the temperature was maintained at 45 °C. The extract was dried in an oven. The dried extract was 
stored at -20 C until use(Nawwar et al., 2012) 
2.5 Cytotoxicity assays against tumor cells  
  The cytotoxicity of the extracts was tested against the HCT116, HEPG-2 and MCF-7 tumor cell lines by 
sulforhodamine B (SRB). Exponentially growing cells were collected using 0.25% trypsin–EDTA and plated in 
96-wellplates at 1000cells/well. Cells were exposed to the extracts for 72h and subsequently fixed with TCA 
(10%) for 1h at 4°C. After many washing, cells were exposed to 0.4% SRB solution for 10min in a dark place 
and subsequently washed with 1% glacial acetic acid. After drying overnight, Tris–HCl was used to dissolve 
the SRB-stained cellsand the color intensity was measured at 540nm.The data are analysis using SigmaPlot 
version 12.0.(Skehan et al., 1990) 
2.6 Cell viability 
 
   sulforhodamine B (SRB) stain, allowed us to distinguish viable and dead cells from each other. Viable and 
dead cells were detected using density measured at 450 nm using microplate reader (Anthos Zenyth-200RT, 
Cambridge, England) (Tolba et al., 2013) 
 
2.6 Apoptosis 
 
Using fluorescein stain, condensed or fragmented nucleus was counted with the assistance of the fluorescent 
microscope (Nikon).  
  
2.8 Statistical Analysis 
The data are analysis using SigmaPlot version 12.0.(Skehan et al., 1990) 
3.Results  
3.1 Cytotoxicity Profile of Momordica charantiaagainst HCT116, MCF-7 and HepG2 cell lines 
  SRB assay was used to assess the anti-proliferative effect of the Momordica charantia extract against three 
different cell lines (HCT116, MCF-7 and HepG2). The extracts showed considerable anti-proliferative activity 
selectively against MCF-7, HCT116 and HepG2. The effect of the Momordica charantia extract was highly 
significant in HepG2 cells than HCT116 cell as well as MCF-7 which showing the IC50 of Momordica 
charantia extract in HepG2 was 0.77µg/ml while in HCT116 was 0.81µg/mland was 1.35µg/ml in MCF-7 cells 
respectively. Also the effect of the Momordica charantia extract was more potent in HCT116 compared to MCF-
7 cells (table 1). 
In the other hand the cell viability parameter showed rise line with increasing dose, striking that the curve of cell 
viability percent gone very slowly with small concentrations (0.01, 0.01,and 1µg/ml) while the difference 
between the concentration 1 µg/ml and concentration 10 µg/ml was highly significant in all cancer cell lines 
(Table 2 figure 1., 2, 3). HepG2 cells are still the most sensitive cancer cell line to (MC) plant extract.   
4 Discussion:  
  Although the way to discover new anticancer drugs seems long, hard and expensive, it is important to give 
people living with cancer longer survival, better quality of life, less of pain and suffering. Just as cancer has the 
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potential to have a variety of types, the plants which produce natural products also have the potential to produce 
different molecules and chemical groups withstand or resist cancer.  
   Cancer which considered as complicated disorder or devastating disease characterized by transformation led to 
uncontrolled cell growth which involves, dysregulation of apoptosis, proliferation, invasion, angiogenesis and 
metastasis (Ichikawa et al., 2006). Consequently, there are two ways trying to keep cancer cell under control, 
Drug design by synthetic chemistry or natural products using plant, bacterial or algae extract. Drugs design by 
synthetic chemistry generally suffering from unwanted side effects because they have been produced under 
conditions far away from living materials. While natural products, produced inside the cell itself which may give 
it an advantage than synthetic products. The anticancer activity of Momordica charantia extract has been 
demonstrated in vitro and in vivo in prostate, breast, ovary and pancreatic, breast cancers in vivo. (Srinivasan et 
al., 2007; Pitchakarn et al., 2010; Fang et al., 2012a; Yung et al., 2015). Our study focused on the effect of crude 
extract of Momordica charantia on liver cancer (HepG2), Human colon cancer (HCT116) and breast cancer 
(MCF-7) in vitro because it had not been reported especially in MCF-7 and HCT116 while HepG2 used as a 
control to compare our results with elder research and publications. Our observations showed that the (MC)plant 
methanolic extract has a potential effect to decrease the proliferation rate of different cancer cell lines specially 
HepG2, liver cancer. The mechanism of action of MC plant extract may due to their chemical contents like 
triterpenoid, which confirmed as anti-proliferative ingredient (Akihisa et al., 2007). It seems that triterpenoid 
showed its effect on the liver, breast and colon cancer in vitro. 
5.CONCLUSION: 
 There is no doubt that this plant gained very high attention to be one of the strong candidate anticancer drugs. 
Despite that, needs further studies to screen and to investigate the mechanism of action in details. 
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Table 1: The IC50 as µg of Momordica charantia extract HCT116, MCF-7 and HepG2 cancer cell. 
Plant extract MCF-7 HCT116 HepG2 
Momordica charantia 1.358 0.8105 0.777 
 
Table (2): The viability % of HCT116, MCF-7 and HepG2 cancer cell after treatment with Momordica charantia 
extract 
Concentration  
µg/ml 
Viability% 
HCT116 MCF-7 HepG2 
0 100 100 100 
0.01 96.53397392 99.48811096 95.00102438 
0.1 92.50171585 97.98546896 87.89182545 
1 92.27865477 96.31770145 79.38946937 
10 2.848318463 6.819682959 3.56484327 
100 2.127659574 1.882430647 2.315099365 
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Fig: (1) Dose response curves of Momordica charantia extract against HCT 
116cells by SRB assay. Cells were treated with various concentrations of 
Momordica charantia for 72 hrs. 
 
 
 
 
 
 
 
 
 
Fig: (2) Dose response curves of  Momordica charantia extract against MCF-7 
cells by SRB assay. Cells were treated with various concentrations of 
Momordica charantia for 72 hrs. 
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Fig: (3) Dose response curves of Momordica charantia extract against HEPG2 
cells by SRB assay. Cells were treated with various concentrations of 
Momordica charantia for 72 hrs. 
 
 
 
